Follow-up Care in Inflammatory Bowel Disease

Abstract

Inflammatory bowel disease (IBD) is a chronic disorder that includes Crohn disease and ulcerative colitis. The disorder is characterized by relapsing and remitting inflammation of the gastrointestinal tract and a high risk for complications, surgeries, and frequent hospitalizations (Peyrin-Biroulet et al., 2016). The prevalence of IBD among adults in the United States (U.S.) was estimated to be 1.3% of the population (3 million) in 2015 and exceeded 0.3% (10 millions) in

A novel inflammatory marker for extensive ulcerative colitis; Endocan

“…It has been stated in studies that more research is needed to measure the extent With timely assessments and treatments, these quality improvement efforts will ultimately improve the quality of care and contribute to the reduction of preventable hospitalizations and healthcare costs from delayed inflammatory bowel disease treatment. Our study is one of the preliminary studies which is conducted to detect the extent of the disease in patients with ulcerative colitis by noninvasive methods with a serum marker such as endocan [1,3,8].…”

Does type 1 diabetes serve as a protective factor against inflammatory bowel disease: A Mendelian randomization study

“…The pathogenesis of IBD is not fully understood; however, it is generally believed to be linked to environmental factors acting on genetically predisposed individuals, triggering an uncontrolled inflammatory response mediated by the immune system[ 4 ]. The chronic inflammatory re-sponse in patients with IBD heightens the risk of cardiovascular diseases, including heart failure and atrial fibrillation, and often necessitates surgeries and frequent hospitalizations[ 5 , 6 ] that can significantly affect the quality of life in patients[ 7 ]. Ulcerative colitis (UC) and Crohn’s disease (CD) represent the two most prevalent forms of IBD[ 8 ].…”

Improving Follow-ups With Gastroenterologists Utilizing an Appointment Scheduling Protocol in Inflammatory Bowel Disease

“…An exhaustive literature review was conducted on evidence-based interventions in appointment scheduling for timely outpatient GI care among patients with IBD (see Figure 1 for the PRISMA flow diagram) (Choe, Wright, & Parian, 2021). Qualitative studies suggest that patients with IBD often face multiple barriers in scheduling GI follow-ups, such as being placed on a long hold, having to speak with multiple staff members about scheduling and/or symptoms, and experiencing a long wait time to see their gastroenterologists at clinics (Lesnovska, Frisman, Hjortswang, Hjelm, & Borjeson, 2017; Schoultz, Macaden, & Watson, 2016).…”

“…The first approach to addressing these scheduling inefficiencies and delays in the GI follow-ups is to implement a clinic-wide appointment scheduling protocol (Choe et al, 2021). In a quality improvement project conducted in a GI university hospital clinic, the clinic director promptly implements scheduling interventions (e.g., overbooking) for the wait time ≥10 days and has increased the proportion of new patients seen by gastroenterologists within 10 days from 35.1% to 79.7 % (Matteson-Kome, Lopez, Sliger, Mathews, & Bechtold, 2014).…”

“…The second approach is to engage gastroenterologists in prioritizing sicker patients based on risk assessment (Choe et al, 2021). Because stratifying disease severity is closely related to an appropriate type of therapy (Vachon & Scott, 2020), delayed evaluation and treatments—especially biologics in moderate-to-severe IBD—can predispose these patients to higher risks for hospitalization, surgery, and mortality (González-Lama et al, 2016; Lewis et al, 2018).…”